Rezolute to announce DMC conclusions in April, says H.C. Wainwright

Rezolute (RZLT) announced that the independent data monitoring committee reviewed safety and pharmacokinetics in eight infant patients in the open-label arm of the ongoing sunRIZE study and approved the company to enroll infants 3 months to 1 year into the double-blind arms of the Phase 3 study, H.C. Wainwright analyst Douglas Tsao tells investors in a research note. The firm thinks the Breakthrough Therapy Designation that was granted to Rezolute in January should help drive rapid enrollment in the U.S. sites., and notes that the DMC will conduct an interim analysis this quarter and plans to make its recommendation in April. H.C. Wainwright reiterates a Buy rating and $14 price target on Rezolute shares.